ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 883,14
1,58%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vaxcyte Inc (PCVX)

  7. Vaxcyte Inc (PCVX) Actualités

PCVX Vaxcyte Inc

65,96
1,41 (2,18%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Vaxcyte Inc PCVX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
1,41 2,18% 65,96 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
66,48 65,46 67,08 65,96 64,55
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/4/202422:05GLOBEVaxcyte to Present at the 23rd Annual Needham Virtual..
05/3/202403:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202403:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202403:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202414:30GLOBEVaxcyte Completes Enrollment of Phase 2 Study Evaluating..
01/3/202422:02EDGAR2Form 144 - Report of proposed sale of securities
01/3/202422:00EDGAR2Form 144 - Report of proposed sale of securities
27/2/202422:58EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202422:02EDGAR2Form 8-K - Current report
27/2/202422:01GLOBEVaxcyte Reports Fourth Quarter and Full Year 2023 Financial..
20/2/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:05GLOBEVaxcyte to Report Fourth Quarter and Full Year 2023..
05/2/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/2/202400:39GLOBEVaxcyte Announces Closing of $862.5 Million Public Offering..
01/2/202422:07EDGAR2Form 144 - Report of proposed sale of securities
01/2/202422:06EDGAR2Form 144 - Report of proposed sale of securities
01/2/202422:05GLOBEVaxcyte to Present at the Guggenheim Healthcare Talks | 6th..
31/1/202423:26EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/1/202423:19EDGAR2Form 8-K - Current report
31/1/202405:37GLOBEVaxcyte Announces Pricing of $750 Million Public Offering
30/1/202422:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/1/202422:01GLOBEVaxcyte Announces Commencement of Proposed Public Offering..
29/1/202414:30GLOBEVaxcyte Completes Enrollment of Phase 1/2 Study Evaluating..
16/1/202422:01GLOBEVaxcyte Appoints Whitney Jones as Chief People Officer
04/1/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:01GLOBEVaxcyte Provides Clinical and Regulatory Progress Update on..
02/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
02/1/202422:03EDGAR2Form 144 - Report of proposed sale of securities
11/12/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/12/202322:15EDGAR2Form 144 - Report of proposed sale of securities
05/12/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202300:35GLOBEVAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in..
01/12/202322:12EDGAR2Form 144 - Report of proposed sale of securities
29/11/202322:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202322:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/11/202314:32EDGAR2Form 8-K - Current report
28/11/202314:30GLOBEVaxcyte Appoints Jacks Lee to Board of Directors
27/11/202322:05EDGAR2Form 8-K - Current report
27/11/202322:00GLOBEVaxcyte Exercises Option and Enters into Manufacturing..
09/11/202314:30GLOBEVaxcyte Doses First Participants in Phase 1/2 Clinical Study..
06/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:07EDGAR2Form 8-K - Current report
06/11/202322:03GLOBEVaxcyte Reports Third Quarter 2023 Financial Results and..
03/11/202321:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202321:07EDGAR2Form 144 - Report of proposed sale of securities
31/10/202321:05GLOBEVaxcyte to Present at Upcoming Investor Conferences
19/10/202315:29DJNVaxcyte Gets FDA Go-Ahead on Pneumococcal Vaccine..
19/10/202314:30GLOBEVaxcyte Announces FDA Clearance of Investigational New Drug..

Dernières Valeurs Consultées

NASDAQ
PCVX
Vaxcyte
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés